Inovio Pharmaceuticals Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy INO?
Source: Globenewswire
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- FDA Approval Delay: On August 8, 2024, Inovio disclosed in its financial results that it expected to submit the INO-3107 Biologics License Application to the FDA by mid-2025, a full year later than initially projected, resulting in a 3.1% drop in stock price the following day.
- Regulatory Uncertainty: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 application for standard review rather than accelerated approval, causing a significant stock price decline of 24.45%, closing at $1.73.
- False Statements Allegations: The lawsuit alleges that Inovio executives made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in the CELLECTRA device, which misled investors regarding the company's prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.810
Low
3.00
Averages
7.33
High
13.00
Current: 1.810
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Faces Securities Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky, LLP alerts investors that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a securities class action lawsuit, with the court setting April 7, 2026, as the deadline for lead plaintiff applications, covering the period from October 10, 2023, to December 26, 2025.
- FDA Approval Misrepresentation: The lawsuit alleges that management repeatedly exaggerated the prospects for FDA accelerated approval and priority review for Inovio's lead product candidate, despite lacking sufficient information to justify the BLA's eligibility for accelerated approval.
- Market Reaction: When the FDA ultimately accepted the BLA for standard review instead of accelerated review, the market reacted negatively, indicating that the commercial implications of accelerated approval were significant and formed a core part of the company's overall investment thesis.
- Investor Transparency: Joseph E. Levi, Esq. emphasized that investors deserve transparency regarding material risks that could affect their investments, particularly in the biotechnology sector where adequate regulatory pathway disclosures are fundamental.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with a successful track record; Rosen Law Firm is recognized for its achievements in securities class actions, having recovered over $438 million for investors in 2019 alone.
- Next Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, emphasizing that until the class is certified, investors must choose legal counsel to protect their interests.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals due to possible false statements made during securities transactions from October 10, 2023, to December 26, 2025, which may have harmed investors' rights.
- FDA Review Update: Although Inovio submitted its Biologics License Application for INO-3107 on December 29, 2025, the FDA indicated that insufficient information was provided to justify accelerated approval, posing regulatory challenges that could delay product launches.
- Significant Stock Decline: Following the FDA announcement, Inovio's stock plummeted by 24.45% to close at $1.73 per share, reflecting a pessimistic market outlook on the company's future prospects, which may further erode investor confidence.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply as lead plaintiff in the class action lawsuit, emphasizing the importance of seeking legal support to protect their rights.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this area.
- Investor Guidance: Investors are advised to select counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the U.S. District Court for the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the FDA submission for INO-3107, severely undermining investor confidence.
- Stock Price Volatility: Following the release of its Q2 2024 financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share, reflecting market concerns over its regulatory prospects and exacerbating investor anxiety.
- FDA Review Impact: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 application on a standard review timeline rather than an accelerated one, causing a 24.45% drop in stock price to $1.73 per share, highlighting significant regulatory challenges and their implications for the company's future commercial outlook.
See More
Reminder of Class Action Lawsuits for Shareholders of Multiple Companies
- Class Action Notification: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging shareholders to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that BlackRock failed to timely disclose investment valuation issues from November 2024 to January 2026, leading to investor misunderstandings about the company's business prospects, which could undermine shareholder confidence and affect stock prices.
- Oracle Lawsuit Impact: Oracle faces a class action from June to December 2025, claiming its AI infrastructure strategy resulted in significant capital expenditure increases without corresponding revenue growth, potentially jeopardizing its debt and credit rating, thereby impacting investor confidence.
- Paysafe and Inovio Overview: Paysafe's lawsuit highlights undisclosed high-risk client issues that may limit revenue growth, while Inovio's manufacturing deficiencies could delay FDA submissions, both posing significant negative implications for future company performance.
See More
Inovio Pharmaceuticals Faces Securities Class Action Lawsuit
- Lawsuit Background: Levi & Korsinsky, LLP alerts investors that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) is facing a securities class action lawsuit, with the court setting April 7, 2026, as the deadline for lead plaintiff applications, covering the period from October 10, 2023, to December 26, 2025.
- FDA Approval Misrepresentation: The lawsuit alleges that management repeatedly exaggerated the prospects for FDA accelerated approval and priority review for Inovio's lead product candidate, despite lacking sufficient information to justify the BLA's eligibility for accelerated approval.
- Market Reaction: When the FDA ultimately accepted the BLA for standard review instead of accelerated review, the market reacted negatively, indicating that the commercial implications of accelerated approval were significant and formed a core part of the company's overall investment thesis.
- Investor Transparency: Joseph E. Levi, Esq. emphasized that investors deserve transparency regarding material risks that could affect their investments, particularly in the biotechnology sector where adequate regulatory pathway disclosures are fundamental.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the prospects of the INO-3107 Biologics License Application, resulting in investor losses.
- Legal Counsel Recommendation: Investors are encouraged to select law firms with a successful track record; Rosen Law Firm is recognized for its achievements in securities class actions, having recovered over $438 million for investors in 2019 alone.
- Next Steps: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the lawsuit, emphasizing that until the class is certified, investors must choose legal counsel to protect their interests.
See More
Faruqi & Faruqi Investigates Potential Claims Against Inovio
- Legal Investigation Launched: Faruq & Faruq LLP is investigating potential claims against Inovio Pharmaceuticals due to possible false statements made during securities transactions from October 10, 2023, to December 26, 2025, which may have harmed investors' rights.
- FDA Review Update: Although Inovio submitted its Biologics License Application for INO-3107 on December 29, 2025, the FDA indicated that insufficient information was provided to justify accelerated approval, posing regulatory challenges that could delay product launches.
- Significant Stock Decline: Following the FDA announcement, Inovio's stock plummeted by 24.45% to close at $1.73 per share, reflecting a pessimistic market outlook on the company's future prospects, which may further erode investor confidence.
- Investor Rights Protection: Faruq & Faruq LLP reminds investors that April 7, 2026, is the deadline to apply as lead plaintiff in the class action lawsuit, emphasizing the importance of seeking legal support to protect their rights.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device manufacturing and overstated prospects for the INO-3107 Biologics License Application, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, showcasing its expertise in this area.
- Investor Guidance: Investors are advised to select counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action process.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Inovio Pharmaceuticals and certain executives in the U.S. District Court for the Eastern District of Pennsylvania, representing investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, seeking damages for violations of federal securities laws.
- False Statements Uncovered: The lawsuit alleges that Inovio made materially false and misleading statements throughout the class period, failing to disclose manufacturing deficiencies in its CELLECTRA device, which led to delays in the FDA submission for INO-3107, severely undermining investor confidence.
- Stock Price Volatility: Following the release of its Q2 2024 financial results on August 9, 2024, Inovio's stock price fell by 3.1% to $8.44 per share, reflecting market concerns over its regulatory prospects and exacerbating investor anxiety.
- FDA Review Impact: On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 application on a standard review timeline rather than an accelerated one, causing a 24.45% drop in stock price to $1.73 per share, highlighting significant regulatory challenges and their implications for the company's future commercial outlook.
See More
Reminder of Class Action Lawsuits for Shareholders of Multiple Companies
- Class Action Notification: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging shareholders to file lead plaintiff motions by the specified deadlines to protect their rights.
- BlackRock TCP Details: The lawsuit alleges that BlackRock failed to timely disclose investment valuation issues from November 2024 to January 2026, leading to investor misunderstandings about the company's business prospects, which could undermine shareholder confidence and affect stock prices.
- Oracle Lawsuit Impact: Oracle faces a class action from June to December 2025, claiming its AI infrastructure strategy resulted in significant capital expenditure increases without corresponding revenue growth, potentially jeopardizing its debt and credit rating, thereby impacting investor confidence.
- Paysafe and Inovio Overview: Paysafe's lawsuit highlights undisclosed high-risk client issues that may limit revenue growth, while Inovio's manufacturing deficiencies could delay FDA submissions, both posing significant negative implications for future company performance.
See More
